Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Objectives:
1. To evaluate the efficacy, in terms of tumor shrinkage, objective response rate, and
down-stage rate, of nivolumab + ipilimumab as neoadjuvant therapy for patients with HCC;
2. To evaluate the safety profile in patients with HCC who receive neoadjuvant nivolumab +
ipilimumab treatment;
3. To collect HCC tumor tissue and peripheral blood samples from the patients for a
comprehensive biomarker evaluation for nivolumab + ipilimumab immunotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital